
Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Investment analysts at HC Wainwright increased their Q3 2027 earnings per share estimates for Fennec Pharmaceuticals in a research note issued on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, up from their previous estimate of $0.34. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2027 earnings at $0.47 EPS.
Fennec Pharmaceuticals Stock Performance
Fennec Pharmaceuticals stock opened at C$19.29 on Thursday. Fennec Pharmaceuticals has a 12 month low of C$7.59 and a 12 month high of C$19.84. The stock’s 50 day simple moving average is C$15.15 and its two-hundred day simple moving average is C$13.24. The firm has a market cap of C$681.03 million, a PE ratio of 643.00 and a beta of 3.90.
Insider Activity at Fennec Pharmaceuticals
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new position in Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 16.86% of the stock is owned by institutional investors and hedge funds.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
